Jump to a section
Buy retatrutide: 30 mg vial, 60 mg vial or 15 mg pen
The 60 mg vial contains twice as much retatrutide as the 30 mg vial and four times as much as the 15 mg pen. Both vials contain powder. The pen contains 3 mL of prepared solution at 5 mg/mL. [1]
Online ordering is not available yet.
PRODUCT IMAGERetatrutide 30 mg vial
30 mg of single-ingredient powder with its own redacted lot report.
- Contents
- 30 mg · 30,000 mcg
- Form
- Freeze-dried powder
- Preparation
- Mixing required
- Sealed storage
- −20°C (−4°F) · dry and dark
Powder lot PL-2609-084: 99.38% HPLC area purity. No separate mg-per-vial content assay.
PRODUCT IMAGERetatrutide 60 mg vial
60 mg of single-ingredient powder with its own matching product image and lot report.
- Contents
- 60 mg · 60,000 mcg
- Form
- Freeze-dried powder
- Preparation
- Mixing required
- Sealed storage
- −20°C (−4°F) · dry and dark
Powder lot PL-2609-087: 99.27% HPLC area purity. No separate mg-per-vial content assay.
PRODUCT IMAGERetatrutide 15 mg prefilled pen
3 mL of prepared solution at 5 mg/mL. No powder-mixing step.
- Cartridge
- 3 mL · 5 mg/mL
- Solution
- Water + 0.9% benzyl alcohol
- Preparation
- Already mixed
- Storage
- 2–8°C (36–46°F) · do not freeze
Batch COA pending.
Product photographs edited to remove supplier branding. Any unresolved specifications are identified on the product card.
| Comparison | 30 mg vial | 60 mg vial | 15 mg pen |
|---|---|---|---|
| Total retatrutide | 30,000 mcg | 60,000 mcg | 15,000 mcg |
| Supplied form | Powder | Powder | Prepared liquid |
| Concentration | Depends on final volume | Depends on final volume | 5 mg/mL |
| Matching redacted COA | PL-2609-084 | PL-2609-087 | Not supplied |
The number on a vial is its total content, not an amount to take at once. The dosage article explains the weekly amounts used in trials, while the main retatrutide guide covers benefits and weight-loss timelines.
Retatrutide 30 mg powder vial
30 mg retatrutide · one sealed powder vial · lot PL-2609-084. Its matching certificate records 99.38% HPLC area purity. The product image shows the 30 mg carton and vial, distinct from the 60 mg option. [2]
Concentration depends on the final mixed volume. For example, 30 mg in a final 3 mL is 10 mg/mL. A 2 mg calculation then gives 0.2 mL, equivalent to 20 U-100 syringe units. The same powder in a final 2 mL is 15 mg/mL; the same 2 mg amount occupies about 0.133 mL.
These are arithmetic examples, not validated mixing recipes or selected treatment amounts. The target-first calculator converts the amount and final volume entered by the reader. The “3 mL vial” description refers to the container; it does not mean 3 mL of liquid is already inside.
Retatrutide 60 mg powder vial
60 mg retatrutide · one sealed powder vial · lot PL-2609-087. This vial has its own product image and certificate, reporting 99.27% HPLC area purity. The 30 mg report is not substituted for it. [3]
At the same final volume, the 60 mg vial makes a solution twice as concentrated as the 30 mg vial. With each prepared to a final 3 mL, the concentrations are 20 mg/mL and 10 mg/mL. A 2 mg target occupies 0.1 mL and 0.2 mL respectively. Reusing the smaller vial's volume would double the peptide amount.
Retatrutide 15 mg pen: 3 mL at 5 mg/mL
The pen contains 15 mg total, already dissolved in 3 mL. Its solution contains water and 0.9% benzyl alcohol. No water is added to the cartridge. At 5 mg/mL, 0.1 mL contains 0.5 mg; 0.4 mL contains 2 mg. [1]
The pen therefore contains half the amount in the 30 mg vial and one quarter of the 60 mg vial. “15 mg” is the cartridge total. “5 mg/mL” is its concentration. Neither number identifies what one mechanical click delivers.
Pen clicks need their own calibration
The product-specific dial scale and liquid volume per click are unconfirmed. A U-100 syringe marking cannot be assumed to equal a pen click. The volume calculation is available; a verified click conversion is not.
The two redacted certificates below cover powder vials. They do not establish the pen's batch number, finished-cartridge content, delivery accuracy or sterility. A report connecting the filled cartridge to a named powder lot has not been supplied.
How much retatrutide is in each format?
Divide total milligrams by the chosen amount to calculate portions. The table uses 2 mg, 4 mg and 8 mg solely as arithmetic examples, without selecting a regimen.
| Amount per calculation | 30 mg vial | 60 mg vial | 15 mg pen |
|---|---|---|---|
| 2 mg | 15 portions | 30 portions | 7½ portions |
| 4 mg | 7½ portions | 15 portions | 3¾ portions |
| 8 mg | 3¾ portions | 7½ portions | 1⅞ portions |
For example, 30 mg contains seven complete 4 mg portions plus a 2 mg remainder. Actual usable yield also depends on transfer losses, residual liquid, pen priming and the validated discard date. A mathematical number of portions does not establish how many weeks an opened container remains usable.
Price per milligram: compare equivalent quantities
Divide each quoted price by 30, 60 or 15 respectively. A 60 mg vial has the same cost per milligram as a 30 mg vial only when it costs exactly twice as much. A 15 mg pen has the same cost per milligram when it costs half the 30 mg vial price.
Prepared convenience, mixing supplies and discarded remainder can change the overall cost. Product prices and online ordering are not yet available.
Storage: frozen powder and refrigerated pen
−20°C / −4°F
Keep the unopened 30 mg and 60 mg vials dry and protected from light.
2–8°C / 36–46°F
Keep capped in its carton. Do not freeze; discard frozen, cloudy or discoloured solution.
Prepared vial solution also has a 2–8°C, light-protected storage specification. Its usable period must come from a validated preparation method. The supplied documents do not specify a universal 28-day or 60-day opened life. [1]
Both powder certificates give 18 September 2028 as the retest/expiry date under their storage conditions. That date does not transfer to a mixed vial or opened pen. The pen's benzyl alcohol content also does not establish its chemical stability after opening. [2][3]
Two redacted retatrutide certificates of analysis
Retatrutide 30 mg — lot PL-2609-084
3 sampled powder vials from lot PL-2609-084; in-house testing. No separate quantitative vial-fill assay or finished-pen testing.
Open redacted COA
Retatrutide 60 mg — lot PL-2609-087
2 sampled powder vials from lot PL-2609-087; in-house testing. No separate quantitative vial-fill assay or finished-pen testing.
Open redacted COAThe 30 mg certificate covers three sampled units from a lot of 300; the 60 mg certificate covers two from a lot of 150. Both report analysis on 19 September 2026 and issue on 3 October 2026. The redacted two-page PDFs preserve the analytical data. [2][3]
The 30 mg report records an observed identity mass of 4731.7 Da, 1.8% water and 0.08 EU/mg endotoxin. The 60 mg report records 4731.6 Da, 1.9% water and 0.06 EU/mg endotoxin. Both state no growth after 14 days under the reported USP <71> sterility method.
The purity tables reconcile: 4,702,407 ÷ 4,731,744 gives 99.38% for the 30 mg lot, and 4,697,467 ÷ 4,732,010 gives 99.27% for the 60 mg lot, rounded to two decimals. These are checks of printed figures, not new laboratory tests.
HPLC area purity describes the relative size of chromatogram peaks. Neither certificate lists a separate quantitative result confirming milligrams in the vial. Both are in-house reports with no independent laboratory attachment, and their conclusions apply to the named powder samples.
Questions & answers.
Is the 60 mg vial a stronger version of retatrutide?
It contains more total retatrutide. At the same final mixed volume it is twice as concentrated as a 30 mg vial. The peptide itself is the same named ingredient.
Does the retatrutide pen contain 5 mg or 15 mg?
15 mg total. It holds 3 mL at 5 mg/mL. Multiply the volume by the concentration to calculate the cartridge content.
How many pen clicks equal 2 mg?
The click calibration is unconfirmed. At 5 mg/mL, 2 mg occupies 0.4 mL, but a verified device specification is needed to convert that volume into clicks.
Which COA belongs to the 60 mg vial?
Lot PL-2609-087, certificate PL-26-00087. The 30 mg vial has its own report: lot PL-2609-084, certificate PL-26-00084.
Does a powder-vial certificate test the prefilled pen?
No. Neither supplied report establishes finished-pen content, sterility, stability or its connection to either powder lot.